Market Overview

UPDATE: Stifel Nicolaus Initiates Medtronic at Hold on Valuation

Share:
Related MDT
Medtronic plc: Medtronic Drug-Coated Balloon for Treatment of Peripheral Arterial Disease Shows Strong Results in Long Lesions
Medtronic Reports Data Showing Quadripolar CRT Technology Optimizing Treatment for Heart Failure Patients
4 Can't Miss Industry Trends With High Growth Potential (Seeking Alpha)

Stifel Nicolaus initiated coverage on Medtronic (NYSE: MDT) with a Hold rating.

Stifel Nicolaus commented, "We are initiating coverage of Medtronic, Inc. (MDT) with a Hold rating on the shares. Fair-to-reasonable valuation for the stock and lack of dramatic upside drivers keep us on the sidelines for the moment. With approximately 50% of Medtronic's business still in pressured "no growth" markets (Cardiac Rhythm Management and Spine) and limited room for further operating margin expansion, we suspect Medtronic's 10.8x forward P/E multiple is unlikely to expand significantly on a relative basis. With MDT shares already trading at the high end of the industry peer group on an EV/EBITDA basis, we prefer to wait for a better entry point on the shares."

Medtronic closed at $41.10 on Monday.

Latest Ratings for MDT

DateFirmActionFromTo
Mar 2015BMO CapitalMaintainsOutperform
Feb 2015JefferiesMaintainsBuy
Dec 2014Bank of AmericaMaintainsBuy

View More Analyst Ratings for MDT
View the Latest Analyst Ratings

Posted-In: Stifel NicolausAnalyst Color Initiation Intraday Update Analyst Ratings

 

Related Articles (MDT)

Around the Web, We're Loving...